bioAffinity Technologies, Inc. Warrant
N/A
USD
N/A
N/A
...
Chart
Financials
Description
BIAFW Company Description
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
BIAFW Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view BIAFW Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of BIAFW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BIAFW's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of BIAFW in WallStreetBets Daily Discussion
BIAFW News
Recent insights relating to BIAFW
CNBC Recommendations
Recent picks made for BIAFW stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in BIAFW
Corporate Flights
Flights by private jets registered to BIAFW
Our Analysis